版塊導(dǎo)航: 正在加載中...

登錄注冊

應(yīng)《網(wǎng)絡(luò)安全法》要求，自2017年10月1日起，未進(jìn)行實(shí)名認(rèn)證將不得使用互聯(lián)網(wǎng)跟帖服務(wù)。為保障您的帳號能夠正常使用，請盡快對帳號進(jìn)行手機(jī)號驗(yàn)證，感謝您的理解與支持！

24小時熱門版塊排行榜

北京石油化工學(xué)院2026年研究生招生接收調(diào)劑公告

返回列表

本帖產(chǎn)生 1 個翻譯EPI ，點(diǎn)擊這里進(jìn)行查看

霜葉

金蟲 (小有名氣)

應(yīng)助: 0 (幼兒園)
金幣: 1205.8
散金: 20
帖子: 262
在線: 39.9小時
蟲號: 284891
注冊: 2006-10-14
性別: MM
專業(yè): 臨床藥理

[求助] 幫忙翻譯一段摘要O(∩_∩)O謝謝

Objectives
The primary aim of the RELIEF study was to evaluate the efficacy and safety of two sequential intravenous (iv)/oral regimens: moxifloxacin iv/oral versus piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC).
Patients and methods
The study had a prospective, randomized, double-dummy, double-blind, multicentre design. Patients ≥18 years were prospectively stratified according to complicated skin and skin structure infection (cSSSI) subtype/diagnosis (major abscess, diabetic foot infection, wound infection or infected ischaemic ulcer), surgical intervention and severity of illness. Diagnoses and disease severity were based on predetermined criteria, documented by repeated photographs, and confirmed by an independent data review committee. Patients were randomized to receive either 400 mg of moxifloxacin iv once daily followed by 400 mg of moxifloxacin orally once daily or 4.0/0.5 g of TZP iv thrice daily followed by 875/125 mg of AMC orally twice daily for 7–21 days. The primary efficacy variable was clinical response at test of cure (TOC) for the per-protocol (PP) population. Clinical efficacy was assessed by the data review committee based on repeated photographs and case descriptions. Clinical trials registry number: NCT 00402727.
Results
A total of 813 patients were randomized. Clinical success rates at TOC were similar for moxifloxacin and TZP–AMC in the PP [320/361 (88.6%) versus 275/307 (89.6%), respectively; P = 0.758] and intent-to-treat (ITT) [350/426 (82.2%) versus 305/377 (80.9%), respectively; P = 0.632] populations. Thus, moxifloxacin was non-inferior to TZP–AMC. Bacteriological success rates were high in both treatment arms [moxifloxacin: 432/497 (86.9%) versus TZP–AMC: 370/429 (86.2%), microbiologically valid (MBV) population]. Moxifloxacin was non-inferior to TZP–AMC at TOC in both the MBV and the ITT populations. Both treatments were well tolerated.
Conclusions
Once-daily iv/oral moxifloxacin monotherapy was clinically and bacteriologically non-inferior to iv TZP thrice daily followed by oral AMC twice daily in patients with cSSSIs.

回復(fù)此樓

» 猜你喜歡

085600，材料與化工321分求調(diào)劑已經(jīng)有5人回復(fù)
求化學(xué)調(diào)劑已經(jīng)有3人回復(fù)
調(diào)劑求院校招收已經(jīng)有3人回復(fù)
材料與化工（0856）304求B區(qū)調(diào)劑已經(jīng)有8人回復(fù)
320分，材料與化工專業(yè)，求調(diào)劑已經(jīng)有11人回復(fù)
0856求調(diào)劑已經(jīng)有10人回復(fù)
266分，求材料冶金能源化工等調(diào)劑已經(jīng)有9人回復(fù)
085600 286分材料求調(diào)劑已經(jīng)有8人回復(fù)
085701環(huán)境工程，267求調(diào)劑已經(jīng)有16人回復(fù)
286求調(diào)劑已經(jīng)有12人回復(fù)

1樓 2013-01-22 15:21:21

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

zjpa

木蟲 (正式寫手)

翻譯EPI: 17
應(yīng)助: 13 (小學(xué)生)
金幣: 1897.4
散金: 88
紅花: 8
帖子: 446
在線: 156.2小時
蟲號: 1258721
注冊: 2011-04-08
性別: MM
專業(yè): 藥物分析

【答案】應(yīng)助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ...
霜葉: 金幣+60, 翻譯EPI+1, ★★★★★最佳答案, 謝謝啦 2013-01-24 16:58:54

RELIEF 研究的主要目的是評估兩個序貫療法—靜脈注射（iv）/口服方案：莫西沙星iv /口服vs哌拉西林/他唑巴坦（TZP）iv，隨后口服阿莫西林/克拉維酸（AMC）—的有效性和安全性。
患者和方法：
本研究采用前瞻性、隨機(jī)、雙模擬、雙盲、多中心設(shè)計(jì)。根據(jù)復(fù)雜性皮膚和皮膚結(jié)構(gòu)感染（cSSSI）亞型/診斷（主要為膿腫、糖尿病足感染、傷口感染或感染缺血性潰瘍）、外科手術(shù)和病情的嚴(yán)重程度，將患者≥18歲進(jìn)行前瞻性分層。診斷和疾病嚴(yán)重程度基于事先確定標(biāo)準(zhǔn)，由重復(fù)照片進(jìn)行記錄，并由一個獨(dú)立數(shù)據(jù)審查委員會進(jìn)行確認(rèn)。患者隨機(jī)分配接受400毫克莫西沙星每日一次iv、隨后400毫克莫西沙星每日一次口服，或4.0/0.5克 TZP每日三次iv、隨后875/125毫克AMC每日兩次口服，持續(xù)7-21天。主要療效變量是符合方案（PP）人群的在治愈試驗(yàn)時的臨床反應(yīng)。臨床療效評價由數(shù)據(jù)審查委員會基于重復(fù)的照片和病例說明進(jìn)行評價。臨床試驗(yàn)注冊號：NCT00402727。
結(jié)果
總共有813例患者進(jìn)行隨機(jī)分配。莫西沙星和TZP-AMC的符合方案 [分別為320/361 (88.6%) vs 275/307 (89.6%)；P = 0.758] ]和“意圖治療” [分別為350/426 (82.2%) vs 305/377 (80.9%)； P = 0.632]人群在治愈試驗(yàn)（TOC）時的臨床治愈率相似。因此，莫西沙星不劣于TZP-AMC。兩個治療組的細(xì)菌學(xué)治愈率均很高[莫西沙星：432/497 (86.9%) vs TZP–AMC: 370/429 (86.2%)，微生物有效（MBV）人群]。莫西沙星在MBV和ITT人群中的TOC不劣于TZP–AMC 。兩種治療均具有良好的耐受性。
結(jié)論
在cSSSI患者中，每日一次靜脈注射/口服莫西沙星單藥治療的臨床和細(xì)菌學(xué)療效，不劣于TZP每天三次靜脈注射、隨后AMC每日兩次口服。

贊一下(1人)

回復(fù)此樓

tryandjusttry

2樓2013-01-24 14:05:24